Rise Therapeutics

Orally Bioavailable Protein Therapeutics

R-2487 Clin0 Sjogren's syndrome, autoimmune diseases; R-5780 Clin0 oncology; undisclosed programs RD undisclosed

Rise Therapeutics is developing oral immunotherapies to treat a wide variety of human diseases. By merging their understanding of immune therapy with discoveries of how the microbiome functions, Rise has created their Tripartite X (TPX) drug delivery platform. TPX is a novel synthetic biology approach that allows oral delivery of protein-based drugs by encapsulating them inside probiotics. Rise’s approach combines low-cost product manufacturing and convenient oral capsule dosing overcoming traditional approaches that require injection or infusion. Rise has established a diverse pipeline at clinical stages for various immune diseases.